The most comprehensive, worldwide survey of salaries, incentives and office organizational structures — offering valuable insights on compensation and the tools to map successful careers within the technology transfer profession is now available for purchase.Learn more > > >
A successful U.S. innovation ecosystem that has supported new products and services since the advent of Bayh-Dole is under threat.
October 5 - 7
The Westin Seattle
Seattle, Washington USA
Get instant access to helpful resources, networking and discounts on AUTM events.
View member benefits »
Get involved by supporting a committee that suits your interests and availability.
Click here to visit AUTM’s new website platform and meet the AUTM members who are in the field, building a better world.
H8 Sharing Data and Assets Across Industry and Academia to Drive the Science Base and Innovation
|Track:||Industry - Academic Relations|
|Target Audience:||All Audiences|
|Moderator:||Malcolm Skingle, Ph.D., GlaxoSmithKline|
|Speakers:||Rowan Douglas, Willis Research Network|
|Helene Rutledge , GlaxoSmithKline|
|Bin Yan, Ph.D., LL.B. , University of Miami W.H Coulter Center|
Increasingly, technology-driven companies are looking to de-risk research and development projects by sharing data and proprietary assets with selected academics in order to expand parts of the science base and to increase their internal knowledge. Many of these projects are co-funded by funding agencies on the assumption that the data generated is deposited into the public domain for all to access. This has driven an interesting dynamic where the corporate company has wanted increased levels of openness and some universities wish to adopt a more secretive approach. Several companies driven by global technology have developed innovative business models with certain universities in recent years in order to increase R&D productivity. These models will be described in detail in order to share what many in industries now consider to be best practice. Recent novel examples from different industrial sectors will be described, including business models from GlaxoSmithKline, Proctor and Gamble, and Willis Ltd, a company specializing in risk adjustment.